首页工具

登录

搜索结果

Search Results for " c-met inhibitor 2 "

26

抑制剂 & 化合物

1

天然产物

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T5349	SCR-1481B1 麦他替尼胺丁三醇,c-Met inhibitor 2	VEGFR; c-Met/HGFR	Angiogenesis; Tyrosine Kinase/Adaptors
	SCR-1481B1 (c-Met inhibitor 2) 能够作用于依赖 Met 激活的癌症，对 VEGFR 具有抑制作用。
T10655	c-Met inhibitor 1 3-[(2-甲基-2H-吲唑-5-基)硫基]-6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-B]哒嗪	c-Met/HGFR	Tyrosine Kinase/Adaptors
	c-Met inhibitor 1 是一种 c-Met 受体信号通路抑制剂，可用于癌症的治疗，包括胶质母细胞瘤、胃癌和胰腺癌。
T13194	CSF1R-IN-2	c-Fms; c-Met/HGFR; Src	Angiogenesis; Tyrosine Kinase/Adaptors
	CSF1R-IN-2 是一种口服具有活力的、有效的 SRC，MET 和 c-FMS 抑制剂，它们的 IC50 值分别为 0.12 nM，0.14 nM 和 0.76 nM。
T21312	Afatinib 阿法替尼,Afatinib free base,BIBW 2992	EGFR; Autophagy	Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Afatinib (BIBW 2992) 是一种不可逆的 EGFR 家族抑制剂，抑制 EGFRwt、EGFRL858R、EGFRL858R/T790M 和 HER2的 IC50分别为0.5 nM、0.4 nM、10 nM 和 14 nM。
T1773	Afatinib Dimaleate 马来酸阿法替尼,双马来酸盐阿法替尼,BIBW2992,Afatinib,BIBW 2992MA2,Afatinib (BIBW2992) Dimaleate	EGFR; HER; Autophagy	Angiogenesis; Autophagy; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	Afatinib Dimaleate (BIBW 2992MA2) 是一种可口服的苯胺基-喹唑啉衍生物和受体酪氨酸激酶表皮生长因子受体家族的抑制剂，具有抗肿瘤活性。它抑制 EGFRwt、EGFRL858R、EGFRL858R/T790M 和 HER2的 IC50分别为0.5 nM、0.4 nM、10 nM 和 14 nM。
T3455	Merestinib LY2801653	Discoidin Domain Receptor (DDR); FLT; c-Met/HGFR; ROS; ROS Kinase	Angiogenesis; Immunology/Inflammation; Tyrosine Kinase/Adaptors
	Merestinib (LY2801653) 是一种有效的口服生物可利用的具有抗肿瘤活性的c-Met 抑制剂。
T6517	Golvatinib E-7050,戈伐替尼	VEGFR; c-Met/HGFR	Angiogenesis; Tyrosine Kinase/Adaptors
	Golvatinib (E-7050) 是一种 c-Met (IC50:14 nM) 和 VEGFR2 (IC50:16 nM) 的双重抑制剂。
T2054	Altiratinib DCC-2701	VEGFR; Tie-2; FLT; Trk receptor; c-Met/HGFR	Angiogenesis; Tyrosine Kinase/Adaptors
	Altiratinib (DCC-2701) 是一种多靶点激酶抑制剂，能够抑制 MET (IC50:2.7 nM)，TIE2 (IC50:8 nM)，VEGFR2 (IC50:9.2 nM)，FLT3 (IC50:9.3 nM)，Trk1 (IC50:0.85 nM)，Trk2 (IC50:4.6 nM) 和 Trk3 (IC50:0.83 nM)。
T6039	TAK-285 TAK285,TAK 285	EGFR; MEK; HER; Aurora Kinase	Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Tyrosine Kinase/Adaptors
	TAK-285 是一种新型 HER2 和 EGFR(HER1) 双重抑制剂，IC50 分别为 17 和 23 nM。它可穿过血脑屏障，有抗肿瘤活性，对 HER1/2 的选择性是 HER4 的 10 倍以上。
T2668	JNK-IN-8 JNK Inhibitor XVI	JNK; c-Kit	MAPK; Tyrosine Kinase/Adaptors
	JNK-IN-8 (JNK Inhibitor XVI) 是一种有效的JNK 抑制剂，抑制JNK1、JNK2和JNK3，IC50分别为 4.7、18.7 和 1 nM。
T6289	Dovitinib TKI258,多韦替尼,CHIR-258,度维替尼	VEGFR; FGFR; FLT; PDGFR; c-Kit	Angiogenesis; Tyrosine Kinase/Adaptors
	Dovitinib (CHIR-258) 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂，具有抗肿瘤作用。
T6479	Dovitinib lactate hydrate Dovitinib (TKI258) Lactate,多韦替尼,Dovitinib Lactate,TKI258	VEGFR; FGFR; FLT; PDGFR; c-Kit	Angiogenesis; Tyrosine Kinase/Adaptors
	Dovitinib lactate hydrate (TKI258) 是一种多靶点的酪氨酸激酶抑制剂，抑制 FLT3，c-Kit，FGFR1/3，VEGFR1/2/3和 PDGFRα/β的 IC50值分别为 1，2，8/9，10/13/8，27/210 nM。
T10654	c-Met-IN-2	c-Met/HGFR	Tyrosine Kinase/Adaptors
	c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
T63656	c-Met-IN-11
	c-Met-IN-11 是 c-MET (IC50: 41.4 nM) 和 VEGFR-2 (IC50: 71.1 nM) 的有效抑制剂。
T26379	1D-2 1D2,1D 2
	1D-2 is a highly potent and exquisitely selective inhibitor of the c-Met protein kinase.
T80874	VEGFR-2/c-Met-IN-1	VEGFR	Angiogenesis; Tyrosine Kinase/Adaptors
	VEGFR-2/c-Met-IN-1为VEGFR-2及c-Met的双重抑制剂，IC50值为138 nM和74 nM，显示出抗肿瘤活性。
T28899	T-1840383
	T-1840383 is an inhibitor of VEGF-induced VEGFR-2 phosphorylation and HGF-induced c-Met phosphorylation in vascular endothelial cells and cancer epithelial cells.
T72759	c-Met/HDAC-IN-2
	c-Met/HDAC-IN-2 是一种高效的c-Met 和HDAC 双重抑制剂，对HDAC1与c-Met 的IC50分别为 18.49 nM 和 5.40 nM。c-Met/HDAC-IN-2 对几种癌细胞具有抗增殖活性。c-Met/HDAC-IN-2 能将 HCT-116 细胞周期阻滞在 G2/M 期，诱导细胞凋亡 (apoptosis)。c-Met/HDAC-IN-2 可用于抗癌耐药研究。
T71636	Golvatinib tartrate
	Golvatinib tartrate is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity.
T71187	Foretinib phosphate
	Foretinib phosphate is an orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers.
T15808	Merestinib dihydrochloride LY2801653 dihydrochloride	ROCK	Cell Cycle/Checkpoint; Cytoskeletal Signaling; Stem Cells
	Merestinib dihydrochloride is an effective and orally bioavailable c-Met inhibitor (Ki=2 nM). It has anti-tumor activities and also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), RO
T14282	Amuvatinib hydrochloride HPK 56 hydrochloride,MP470 hydrochloride	Others	Others
	Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret and is also a DNA repair suppressor through suppression of DNA repai
T71382	KRC-108
	KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these cancer cell lines. KRC-108 was also effective for the inhibition of tumo...
T6193	Dovitinib Dilactic Acid Dovitinib (TKI-258) Dilactic Acid,TKI258 Dilactic acid	VEGFR; FGFR; FLT; c-Kit	Angiogenesis; Tyrosine Kinase/Adaptors
	Dovitinib Dilactic Acid (Dovitinib(TKI-258) Dilactic Acid) 是 Dovitinib 的双乳酸，是一种多靶点 RTK 抑制剂，主要用于 III 类 (FLT3/c-Kit)，IC50 为 1 nM/2 nM，对 IV 类 (FGFR1/ 3) 和 V 类 (VEGFR1-4) RTK，IC50 为 8-13 nM，对 InsR、EGFR、c-Met、EphA2、Tie2、IGFR1 和 HER2 的效力较低。
T79572	MAPK-IN-2	EGFR	Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors
	MAPK-IN-2 (化合物3h)是一种携带抗肿瘤活性的高效MAPK抑制剂。它在多个癌细胞系中有效抑制了细胞增殖，并对MAPK途径表现出强大的抑制效果（EGFRWT IC50=281 nM, c-MET IC50=205 nM, B-RAFWT IC50=112 nM, CDK4/6 IC50=95和184 nM），对突变型EGFR和B-RAF亦展现出高效力（EGFRT790M IC50=69 nM, B-RAFV600E IC50=83 nM）。
T83911	CYY292
	CYY292是一种针对PDGFRα、PDGFRβ、FGFR1、-2和-3的抑制剂（IC50分别为5.35、4.6、28、28和78 nM）。该化合物对这些激酶的选择性高于FGFR4（IC50 > 1,000 nM），但也能抑制c-Kit、VEGFR2、VEGFR1和胰岛素样生长因子1受体（IGF-1R；IC50分别为67、33、36和75 nM），以及EGFR、布鲁顿酪氨酸激酶（BTK）、细胞周期依赖性激酶4（Cdk4）/cyclin D3和MET（IC50分别为128、198、214和396 nM）。CYY292抑制MG-63、U2OS、MNNG/HOS和Saos-2骨肉瘤细胞的增殖（IC50分别为0.84、0.76、1.36和0.72 µM）。在0.3和0.5 µM的浓度下，它抑制U87MG和LN-229胶质母细胞瘤细胞的迁移和侵袭。CYY292（30 mg/kg）在U87MG原位小鼠异种移植模型中降低肿瘤体积并增加生存率。

化合物

Cat.No: T5349

Synonym: 麦他替尼胺丁三醇,c-Met inhibitor 2

Target: VEGFR, c-Met/HGFR

c-Met inhibitor 1

Cat.No: T10655

Synonym: 3-[(2-甲基-2H-吲唑-5-基)硫基]-6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-B]哒嗪

Target: c-Met/HGFR

Cat.No: T13194

Target: c-Fms, c-Met/HGFR, Src

Cat.No: T21312

Synonym: 阿法替尼,Afatinib free base,BIBW 2992

Target: EGFR, Autophagy

Afatinib Dimaleate

Cat.No: T1773

Synonym: 马来酸阿法替尼,双马来酸盐阿法替尼,BIBW2992,Afatinib,BIBW 2992MA2,Afatinib (BIBW2992) Dimaleate

Target: EGFR, HER, Autophagy

Cat.No: T3455

Synonym: LY2801653

Target: Discoidin Domain Receptor (DDR), FLT, c-Met/HGFR, ROS, ROS Kinase

Cat.No: T6517

Synonym: E-7050,戈伐替尼

Target: VEGFR, c-Met/HGFR

Cat.No: T2054

Synonym: DCC-2701

Target: VEGFR, Tie-2, FLT, Trk receptor, c-Met/HGFR

Cat.No: T6039

Synonym: TAK285,TAK 285

Target: EGFR, MEK, HER, Aurora Kinase

Cat.No: T2668

Synonym: JNK Inhibitor XVI

Target: JNK, c-Kit

Cat.No: T6289

Synonym: TKI258,多韦替尼,CHIR-258,度维替尼

Target: VEGFR, FGFR, FLT, PDGFR, c-Kit

Dovitinib lactate hydrate

Cat.No: T6479

Synonym: Dovitinib (TKI258) Lactate,多韦替尼,Dovitinib Lactate,TKI258

Target: VEGFR, FGFR, FLT, PDGFR, c-Kit

Cat.No: T10654

Target: c-Met/HGFR

Cat.No: T63656

Cat.No: T26379

Synonym: 1D2,1D 2

VEGFR-2/c-Met-IN-1

Cat.No: T80874

Target: VEGFR

Cat.No: T28899

c-Met/HDAC-IN-2

Cat.No: T72759

Golvatinib tartrate

Cat.No: T71636

Foretinib phosphate

Cat.No: T71187

Merestinib dihydrochloride

Cat.No: T15808

Synonym: LY2801653 dihydrochloride

Target: ROCK

Amuvatinib hydrochloride

Cat.No: T14282

Synonym: HPK 56 hydrochloride,MP470 hydrochloride

Target: Others

Cat.No: T71382

Dovitinib Dilactic Acid

Cat.No: T6193

Synonym: Dovitinib (TKI-258) Dilactic Acid,TKI258 Dilactic acid

Target: VEGFR, FGFR, FLT, c-Kit

Cat.No: T79572

Target: EGFR

Cat.No: T83911

Cat. No.	Product Name	Target	Signaling Pathways
T13108	Pamufetinib H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115	VEGFR; c-Met/HGFR	Angiogenesis; Tyrosine Kinase/Adaptors
	Pamufetinib (TAS-115) 是VEGFR 和c-Met/HGFR 抑制剂，能够抑制 rVEGFR2 (IC50:30 nM)和 rMET (IC50:32 nM)的活性。

天然产物

Cat.No: T13108

Synonym: H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115

Target: VEGFR, c-Met/HGFR

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼